BACKGROUND: Vascular endothelial growth factor (VEGF) is upregulated in pulmonary alveolarization. However, developmental expression of pulmonary VEGF and its possible role in the pathogenesis of CDH are not well described. METHODS: Timed-pregnant VEGF-LacZ mice, possessing a beta-galactosidase reporter introduced into the 3' region of the VEGF gene, were used to examine fetal lung gene expression in a model of nitrofen-induced CDH. RESULTS: VEGF gene expression increased from embryonic day 13 until its peak at embryonic day 16 and then decreased until term in all groups. This pattern was most apparent in the periphery with smaller differences noted in central lung locations. Expression of VEGF/beta-gal in the lungs of nitrofen-treated mice was less than controls at all time-points (P <.0001) The type-II pneumocyte population did not significantly differ between the groups. Study concentrations of nitrofen showed no effect on vascular endothelial proliferation in vitro. CONCLUSIONS: Nitrofen downregulates the production of VEGF during gestation and attenuates the peak seen at the onset of the canalicular stage, despite preservation of type-II pneumocytes. This effect was most pronounced in peripheral lung tissue. The authors speculate that altered VEGF expression may have a pivotal role in the pathogenesis of nitrofen-induced CDH.
BACKGROUND:Vascular endothelial growth factor (VEGF) is upregulated in pulmonary alveolarization. However, developmental expression of pulmonary VEGF and its possible role in the pathogenesis of CDH are not well described. METHODS: Timed-pregnant VEGF-LacZ mice, possessing a beta-galactosidase reporter introduced into the 3' region of the VEGF gene, were used to examine fetal lung gene expression in a model of nitrofen-induced CDH. RESULTS:VEGF gene expression increased from embryonic day 13 until its peak at embryonic day 16 and then decreased until term in all groups. This pattern was most apparent in the periphery with smaller differences noted in central lung locations. Expression of VEGF/beta-gal in the lungs of nitrofen-treated mice was less than controls at all time-points (P <.0001) The type-II pneumocyte population did not significantly differ between the groups. Study concentrations of nitrofen showed no effect on vascular endothelial proliferation in vitro. CONCLUSIONS:Nitrofen downregulates the production of VEGF during gestation and attenuates the peak seen at the onset of the canalicular stage, despite preservation of type-II pneumocytes. This effect was most pronounced in peripheral lung tissue. The authors speculate that altered VEGF expression may have a pivotal role in the pathogenesis of nitrofen-induced CDH.
Authors: Duy T Dao; Lorenzo Anez-Bustillos; Amy Pan; Alison A O'Loughlin; Paul D Mitchell; Gillian L Fell; Meredith A Baker; Bennet S Cho; Prathima Nandivada; Arthur P Nedder; Charles J Smithers; Nancy Chen; Robert Comeau; Kevin Holmes; Susan Kalled; Angela Norton; Bohong Zhang; Mark Puder Journal: Surgery Date: 2018-09-05 Impact factor: 3.982
Authors: Maria de Lurdes Pinto; Paula Rodrigues; Ana Cláudia Coelho; Maria dos Anjos Pires; Dario Loureiro dos Santos; Carlos Gonçalves; Vasco António Bairos Journal: Int J Exp Pathol Date: 2007-12 Impact factor: 1.925
Authors: Lumeng J Yu; Victoria H Ko; Duy T Dao; Jordan D Secor; Amy Pan; Bennet S Cho; Paul D Mitchell; Hiroko Kishikawa; Diane R Bielenberg; Mark Puder Journal: Sci Rep Date: 2021-06-04 Impact factor: 4.379
Authors: L Sbragia; A C C Nassr; F L L Gonçalves; A F Schmidt; C C Zuliani; P V Garcia; R M Gallindo; L A V Pereira Journal: Braz J Med Biol Res Date: 2014-01-17 Impact factor: 2.590